SLIDE 7 Page 7
RCT: VIDARIS Trial, JAMA, October 2012
- 322 healthy adults in New Zealand
- 100,000 IU D3 monthly
- 18 months follow-up
25(OH) D URI incidence Vitamin D 48 ng/mL 3.7 infections/person Placebo 25 ng/mL 3.7 infections/person
VITAL (VIT D and OmegA-3 TriaL)
- RCT n = 25,871
- Vitamin D3 2000 IU daily; adherence 80%
- Follow-up:
Median 5.3 years (3.8-6.1)
– 67.1 years old – 51% female – 20% Black, 4% Hispanic, 71% NHW
Manson et al, NEJM, 2018
VITAL: Vitamin D Results
Outcome Hazard Ratio (95% CI) Cancer* 0.96 (0.88-1.06) Breast Cancer 1.02 (0.79-1.31) Death from Cancer 0.83 (0.67-1.02) Major CVD Event* 0.97 (0.85-1.12) Death from CVD 1.11 (0.88-1.40) Myocardial Infarction 0.96 (0.78-1.19) Death from Any Cause 0.99 (0.87-1.12)
* Co-Primary Endpoints ; 24 endpoints reported in Table 2
Manson et al, NEJM, 2018
US Preventive Services Task Force
– Vitamin D for fracture prevention (I) – Vitamin D for fall prevention (D)
I = Insufficient evidence: the balance of benefits and harms cannot be determined D = The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.